N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=9 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
Phase 2 N=32 Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Atopic Dermatitis
Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants
N/A N=148,166 Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
Atopic Dermatitis Eczema · Atopic Dermatitis · Eczema
Primary: Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes — 76095 Participants
Phase 2 N=60 Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change
Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
Phase 2 N=20 Effect of Benralizumab in Atopic Dermatitis
Dermatitis, Atopic · Dermatitis · Eczema
Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2
Phase 3 N=65 8-Week Atopic Dermatitis (AD) Treatment Study
Atopic Dermatitis Eczema
Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05
N/A N=15 Acupressure in Pruritus for Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters
Phase 4 N=90 Combination Therapy for Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05
Phase 4 N=461 A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24 — 74.6; 48.1; 68.5; 29.3 percentage of…
Phase 3 N=920 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or…
Phase 2 N=200 A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
Phase 3 N=671 Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Dermatitis, Atopic
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 — 10.3; 37.9; 37.2…
Phase 2 N=15 Topical NanoDox® for Atopic Dermatitis
Dermatitis, Atopic
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants
Phase 3 N=708 Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Dermatitis, Atopic
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 — 8.5; 36.1; 36.4…
Phase 2 N=13 A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
Atopic Dermatitis
Primary: Change in Gene Expression Typically Associated With Atopic Dermatitis in Lesional Skin Biopsies From Baseline to Week 4 — 0.212; 0.043; 0.155; 0.048 fold change
Phase 2 N=54 Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
Atopic Dermatitis (AD)
Primary: Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16 — -5.8; -75.2 percent change — p=< 0.0001
Phase 2 N=16 Apremilast for Atopic Dermatitis - A Pilot Study in Adults
Atopic Dermatitis
Primary: Change in EASI Scores — -8.8; -8.2 units on a scale
Phase 3 N=912 Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
Atopic Dermatitis
Primary: Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 — 16.3; 69.6; 79.7…
Phase 2 N=98 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch) — 7.3; 7.26; 4.27; 4.6 score on a scale — p== 0.249
Phase 2 N=50 Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 — -74.45; -41.43 percent change — p=<0.001
Phase 1 N=15 Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients
Atopic Dermatitis Eczema
Primary: Relative Abundance of Staphylococcus Aureus Compared to Baseline — 0.106; 12.9 Relative abundance of S. aureus
Phase 2 N=139 Effect of OC000459 on Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16 — -3.8; -6.1 units on a scale
Phase 2 N=194 Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
Atopic Dermatitis
Primary: Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16 — 83.7; 83.3 Percentage of participants
Phase 2 N=327 Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)
Atopic Dermatitis
Primary: Change From Baseline in Numeric Rating Scale (NRS) for Pruritus in Treated Population Compared to Vehicle Population at Week 8 — -3.8; -2.9; -2.9 score on a scale…
Phase 2 N=380 Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16 — -75.5; -70.5; -67.4; -64.9 Percent change — p=<0.0001
Phase 2 N=273 Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score — -48.33; -49.72; -61.07; -57.35 percentage of score change — p=< 0.001
Phase 3 N=631 Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 — 15.1; 50.0; 53.8 percentage of participants — p=< 0.0001
N/A N=368 Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
Dermatitis, Atopic
Primary: Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatitis, Intradermal - Influenza B — 34.4; 22.5 percentage of participants…